SEC Form 4 · accession 0000920465-18-000019
LA JOLLA PHARMACEUTICAL CO · LJPC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura L. Douglass
Director
Period of report
May 30, 2018
Accepted (ET)
Jun 1, 2018 · 9:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920465
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 30, 2018 | M | 500 | $6.00 | A | 500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.00 | May 30, 2018 | M | 500 | D | — | Nov 21, 2023 | Common Stock | 500 | 13,500 | D |
Explanation of responses
- F1These options represent a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one quarter of which shall be fully vested and exercisable on October 14, 2014, with the remaining 13,500 shares vesting monthly thereafter over the next three years in 36 equal increments of 375 shares.